Press
-
Exosome Diagnostics Achieves ISO 13485:2016 Certification
-
Exosome Diagnostics Announces Bladder Cancer Surveillance Panel
-
June 2022 Newsletter
-
Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
-
Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain
-
Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test
-
Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test
-
Exosome Diagnostics Obviates Tissue Biopsies
-
Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients